TES Pharma announces the publication of a Journal of Medicinal Chemistry paper “α-Amino-β-carboxymuconate-ε-semialdehyde Decarboxylase (ACMSD) Inhibitors as Novel Modulators of De Novo Nicotinamide Adenine Dinucleotide (NAD+) Biosynthesis” (DOI: 10.1021/acs.jmedchem.7b01254) covering the first drug-like inhibitors of ACMSD.

The TES Pharma compounds are shown to increase de novo NAD+ biosynthesis in cellular systems and are being progressed through animal model studies leading to candidate selection.

As inhibitors of ACMSD these compounds will be useful for the prevention and/or treatment of diseases and disorders associated with defects in NAD+ homeostasis, such as: metabolic disorders, chronic inflammatory diseases, kidney diseases, and diseases associated with ageing.